Impact of Saroglitazar on the Metabolic Profile in Type 2 Diabetes Mellitus Patients with Moderate to Severe Hypertriglyceridemia

Background: Saroglitazar is dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist and approved for elevated triglyceride (TG) reduction in type 2 diabetes mellitus (T2DM) and Non-alcoholic fatty liver disease in India. This study was conducted to evaluate the effect of Saroglitazar in T2DM patients with moderate to severe hypertriglyceridemia to contribute to nationwide existing data of real time clinical practice. Methods: It is a retrospective, observational study conducted from April 2023-2024, among T2DM participants with either moderate hypertriglyceridemia (200-499 mg/dl) or severe hypertriglyceridemia (>500 mg/dl) who were prescribed Saroglitazar 4 mg once daily and followed up for 6 months with laboratory parameters (blood sugar and lipid profile). Results: A total of 53 patients’ data on demographic and clinical profile was collected and analysed. Saroglitazar, in addition with oral antidiabetic and lipid lowering medication showed statically significant improvement in total cholesterol, triglyceride and HbA1c at 6 months follow-up without any serious adverse events. Conclusion: In T2DM with moderate to severe hypertriglyceridemia, saroglitazar as an add on to statins is an effective and safe therapeutic option to reduce elevated TG and other lipid and glycemic parameters.